Skip to main content

Table 1 Patient characteristics

From: Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial

  N = 113
Characteristic  
  Age, years 66.5 ± 7.6
  Male gender 101 (89.4%)
  Body-mass index, kg/m2 28.4 ± 3.9
  Diabetes mellitus 33 (29.2%)
  Current smoker 15 (13.3%)
  Hypertension 88 (77.9%)
  Hyperlipidemia 99 (87.6%)
  Acute coronary syndrome* 21 (18.6%)
  Heart failure NYHA class 3-4 23 (20.4%)
Preoperative laboratory values  
  Baseline high-density lipoprotein, mg/dL 38.4 ± 11.2
  Baseline low-density lipoprotein, mg/dL 72.8 ± 30.0
  Baseline creatinine, μmol/L 89.0 ± 17.5
Preoperative medication use  
  Aspirin 104 (92.0%)
  Clopidogrel 12 (10.6%)
  Statin 101 (89.4%)
  Beta-blocker 87 (77.0%)
  Angiotensin converting enzyme  
  Inhibitor 57 (50.4%)
Postoperative medication use (at discharge)  
  Aspirin 113 (100%)
  Clopidogrel 56 (49.6%)
  Statin 103 (91.2%)
  Beta-blocker 105 (92.9%)
  Angiotensin converting enzyme  
  Inhibitor 40 (35.4%)
Operative details  
  Number of distal anastomoses 3.5 ± 0.7
  Left internal thoracic graft 112 (99.1%)
  Right internal thoracic graft 22 (19.5%)
  Cross-clamp time, min 64.5 ± 20.1
  Cardiopulmonary bypass time, min 90.1 ± 24.6
  Off-pump surgery 4 (3.5%)
Length of stay  
  Duration in intensive care, days 1.4 ± 1.0
  Duration in hospital, days 8.7 ± 5.8
  1. NYHA New York Heart Association.
  2. *Recent acute coronary syndrome within 1 month.